Valerie P Grignol

8PUBLICATIONS
13CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Solid tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 28, 2026
Correction: Tinoco et al. Clear Cell and Histiocytic/Dendritic Cell Sarcomas: Clinical Outcomes, Molecular Features, and Diagnostic Pitfalls. Cancers 2026, 18, 641.

|Jul 12, 2026
Outcomes of Talimogene Laherparepvec in Soft Tissue Sarcoma.

|Feb 27, 2026
Clear Cell and Histiocytic/Dendritic Cell Sarcomas: Clinical Outcomes, Molecular Features, and Diagnostic Pitfalls.

Gabriel Tinoco, Marium Husain, David Liebner

|Sep 17, 2025
Blockade of interleukin-6 (IL-6) signaling in dedifferentiated liposarcoma (DDLPS) decreases mouse double minute 2 (MDM2) oncogenicity via alternative splicing.

Abeba Zewdu, Danielle Braggio, Gonzalo Lopez

|Jan 08, 2025
Oncogenic Functions of Alternatively Spliced MDM2-ALT2 Isoform in Retroperitoneal Liposarcoma.

Fernanda Costas C de Faria, Safiya Khurshid, Patricia Sarchet

|Jul 17, 2024
Use of neoadjuvant paclitaxel in breast angiosarcoma-Impact on surgical resection and response rates.

Luke V Selby, Emma Clark, James L Chen

Pageof 2

Frequent Collaborators

2 joint publications

Raphael E Pollock

2 joint publications

Scott Lenobel

2 joint publications

Gabriel Tinoco

2 joint publications

Marium Husain